background
laboratorybas
respiratori
pathogen
rp
result
often
avail
late
influenc
clinic
decis
hospitalis
antibiot
treatment
due
time
delay
transport
specimen
test
schedul
wardbas
ie
point
care
poc
test
provid
rapid
result
may
alter
clinic
manag
pathway
method
rp
polymeras
chain
reaction
pcr
system
place
three
inpati
outpati
medic
area
patient
present
influenzalik
ill
upper
respiratori
tract
infect
lower
rti
recruit
januaryjuli
poc
test
occur
even
day
month
intervent
routin
laboratorybas
rp
pcr
test
atyp
serolog
odd
day
control
primari
outcom
length
hospit
stay
secondari
outcom
impact
use
antimicrobi
readmiss
allcaus
mortal
length
ward
stay
turnaround
time
tat
time
result
admiss
result
elig
patient
includ
control
arm
intervent
arm
control
arm
patient
intervent
arm
patient
rp
detect
poc
test
associ
primari
outcom
measur
length
stay
reduc
tat
h
h
p
prescrib
decis
differ
studi
arm
p
antivir
given
intervent
associ
reduct
median
time
first
dose
h
allow
appropri
treatment
mycoplasma
infect
continu
next
page
respiratori
tract
infect
rti
place
signific
burden
health
system
global
particularli
annual
respiratori
season
epidem
diagnost
test
respiratori
pathogen
rp
usual
laboratorybas
inher
delay
time
result
relat
specimen
transit
laboratori
laboratori
test
schedul
exampl
day
andor
perform
weekend
holiday
reason
due
natur
test
cultur
serolog
batch
molecular
test
result
rare
avail
clinician
patient
first
assess
consequ
though
respiratori
virus
frequent
isol
commun
acquir
pneumonia
cap
report
respons
cap
case
admit
uk
hospit
decis
manag
viral
rti
treat
bacteri
infect
includ
mycoplasma
pneumonia
chlamydia
pneumonia
atyp
bacteria
base
upon
clinic
scenario
sever
criteria
score
thu
proport
infect
inappropri
manag
antibiot
result
may
arriv
late
influenza
treatment
effect
world
health
organ
state
antimicrobi
resist
threaten
effect
prevent
treatment
everincreas
rang
infect
centr
evid
base
medicin
highlight
consider
number
new
diagnost
technolog
develop
underpin
ration
prescrib
antibiot
extend
antivir
point
care
poc
test
elimin
need
specimen
transport
test
laboratori
perform
demand
ward
staff
provid
faster
result
poc
test
may
influenc
earli
treatment
decis
hospit
admiss
allow
earlier
discharg
target
antimicrobi
prescript
better
antimicrobi
stewardship
poc
test
also
reduc
crosstransmiss
subsequ
nosocomi
outbreak
relat
viral
rti
case
undiagnos
patient
place
appropri
isol
howev
current
poc
test
respiratori
virus
gener
antigen
detect
test
usual
detect
influenza
respiratori
syncyti
viru
rsv
sensit
suboptim
biofir
respiratori
panel
biofir
diagnost
salt
lake
citi
ut
biomerieux
compani
detect
respiratori
virus
influenza
viru
type
b
influenza
subtyp
adenoviru
coronavirus
human
metapneumoviru
human
rhinovirusenteroviru
parainfluenza
viru
type
rsv
bacteria
mycoplasma
pneumonia
chlamydia
pneumonia
bordetella
pertussi
lend
poc
test
small
desktop
fullyautom
nest
multiplex
pcr
enclos
dispos
pouch
requir
min
handson
time
result
avail
hour
though
expens
singl
low
multiplex
laboratori
poc
test
clinic
outcom
reduc
length
stay
reduct
inappropri
antimicrobi
usag
result
rapid
extend
panel
may
offset
test
cost
thu
understand
clinic
util
poc
test
earli
patient
admiss
import
undertook
studi
assess
rp
panel
poc
test
compar
routin
laboratorybas
detect
method
order
assess
impact
length
stay
antibiot
util
first
studi
knowledg
wardstaff
perform
rp
panel
poc
test
aim
studi
determin
whether
adult
present
upper
respiratori
tract
infect
urti
influenzalik
ill
ili
lower
respiratori
tract
infect
lrti
rp
panel
poc
test
compar
routin
laboratorybas
rp
test
associ
length
hospit
stay
antimicrobi
use
studi
took
place
bed
teach
tertiari
referr
site
twosit
bed
acut
nh
hospit
trust
londonfour
system
place
sideroom
across
three
adult
year
ward
two
acut
medic
unit
amu
medic
assess
centr
mac
amu
bed
shortstay
acut
medic
ward
patient
admit
emerg
depart
ed
mac
area
outpati
refer
review
clinician
open
daili
pm
mac
patient
assess
admit
amu
discharg
quasirandomis
trial
design
use
patient
enrol
control
arm
odd
day
month
intervent
arm
even
day
month
pragmat
design
could
implement
studi
ward
studi
blind
studyward
staff
educ
studi
consent
take
given
staff
inform
sheet
train
use
respiratori
panel
per
manufactur
instruct
compet
assess
conduct
staff
requir
person
protect
equip
perform
assay
test
order
perform
studyward
staff
howev
unabl
test
eg
due
clinic
duti
studi
investig
work
weekday
pm
halfday
weekend
bank
holiday
perform
test
order
interpret
result
hour
studyward
staff
consult
standard
oper
procedur
describ
pathogen
type
diseas
associ
group
risk
sever
infect
medic
manag
infect
control
precaut
requir
also
direct
contact
number
studi
investig
avail
hour
elig
patient
identifi
ward
staff
studi
staff
written
inform
consent
obtain
ward
staff
patient
particip
control
arm
combin
nose
throat
floccul
swab
copan
diagnost
itali
place
viral
transport
medium
vtm
copan
transport
laboratori
hospit
porter
routin
standard
routin
diagnost
assay
viral
pathogen
use
control
arm
inhous
develop
realtim
pcr
separ
multiplex
assay
influenza
matrix
gene
rna
rna
influenza
viru
rna
influenza
b
viru
rna
rhinoviru
rna
rsv
subgroup
subgroup
b
rna
parainfluenza
virus
rna
human
metapneumoviru
rna
adenoviru
monoplex
outsid
studi
rapidpoc
rp
test
hospit
request
clinic
team
mycoplasma
pneumonia
chlamydia
pneumonia
test
control
arm
use
laboratori
routin
complement
fixat
test
cft
launch
diagnost
kent
uk
tc
bioscienc
buckingham
uk
comparison
pathogen
detect
routin
diagnost
test
shown
tabl
routin
test
perform
site
qualifi
health
care
scientist
pcr
result
avail
intervent
arm
combin
nose
throat
floccul
swab
copan
diagnost
itali
place
viral
transport
medium
vtm
copan
thereaft
rehydr
buffer
vtm
introduc
pouch
wardbas
staff
poc
test
even
day
month
intervent
arm
valid
routin
method
ensur
satisfactori
perform
characterist
head
head
comparison
includ
part
studi
extern
qualiti
control
molecular
diagnost
qcmd
glasgow
uk
intern
qualiti
control
specimen
test
studi
use
approv
trust
point
care
test
committe
result
upload
hospit
result
report
system
posit
result
studi
arm
telephon
microbiologist
virologist
health
care
provid
antimicrobi
stewardship
activ
chang
studi
diagnost
specimen
eg
bacteri
cultur
sent
laboratori
usual
studi
arm
result
includ
analysi
inclus
criteria
patient
year
age
mental
capac
give
written
inform
consent
present
urtiili
defin
symptom
includ
fever
feel
feverish
chill
cough
sore
throat
runni
stuffi
nose
muscleach
bodyach
headach
fatigu
tired
possibl
vomit
diarrhoea
lrti
patient
meet
inclus
criteria
evid
suspicion
bacteri
infect
affect
site
respiratori
tract
exclud
opportun
particip
studi
patient
request
withdraw
studi
exclud
analysi
primari
outcom
studi
length
hospit
stay
defin
time
hospit
admiss
hospit
discharg
rp
panel
rel
expens
consum
capit
purchas
system
depend
upon
countri
compar
current
employ
routin
test
per
test
standard
laboratori
method
howev
averag
cost
manag
pneumonia
commun
estim
per
episod
compar
hospitalis
patient
uk
us
thu
poc
result
allow
earlier
discharg
consequ
financi
save
shorter
hospit
stay
may
offset
extra
test
cost
prove
costbenefici
henc
choic
primari
outcom
secondari
outcom
antimicrobi
prescript
antibiot
versu
none
durat
time
prescript
within
first
h
patient
stay
prescrib
decis
within
h
diagnost
result
investig
start
stop
deescal
escal
continu
use
assess
chief
investig
readmiss
rate
allcaus
mortal
within
day
test
length
studyward
stay
ie
remov
length
stay
subsequ
ward
patient
transfer
relev
escal
defin
addit
antibiot
exist
antibiot
therapi
substitut
current
agent
broader
agent
deescal
cessat
antibiot
antibiot
prescrib
substitut
narrow
agent
collect
data
prospect
retrospect
electron
patient
record
epr
electron
patient
medicin
administr
system
epma
case
enrol
patient
hospit
administr
system
occur
examin
initi
antibiot
therapi
physician
ward
ed
therefor
neg
time
antibiot
administr
ward
correct
zero
hour
antibiot
defin
turnaround
time
tat
test
time
hospit
admiss
time
result
system
intervent
time
result
epr
control
patient
collect
demograph
data
charlson
comorbid
score
time
admiss
score
patient
diagnosi
communityacquir
pneumonia
earli
warn
score
ew
peripher
white
cell
count
wcc
creactiv
protein
crp
day
week
admiss
type
lrti
eg
infect
exacerb
chronic
obstruct
pulmonari
diseas
copd
bronchiti
pneumonia
record
power
calcul
base
upon
length
stay
previous
observ
day
studi
ward
rapid
pathogen
identif
associ
reduct
mean
hospit
length
stay
one
studi
day
day
approx
p
reduct
length
stay
lo
intervent
arm
sampl
size
calcul
indic
sampl
size
case
arm
requir
achiev
power
detect
differ
null
hypothesi
group
mean
day
h
base
upon
data
collect
studi
ward
altern
hypothesi
mean
group
day
h
known
group
standard
deviat
signific
level
alpha
primari
outcom
analys
linear
regress
model
logtransform
length
stay
data
accord
prespecifi
analysi
plan
individu
patient
taken
unit
analysi
secondari
outcom
analys
use
linear
regress
model
continu
outcom
data
logist
regress
binari
outcom
neg
binomi
regress
count
outcom
data
patientrel
outcom
adjust
multipl
prespecifi
potenti
confound
age
sex
charlson
score
ew
wcc
crp
pearson
chisquar
test
use
test
differ
arm
categor
antibiot
prescrib
decis
pvalu
calcul
mont
carlo
replic
avoid
problem
associ
small
cell
count
associ
usual
asymptot
pvalu
ttest
use
compar
time
test
two
arm
plan
subgroup
analysi
perform
primari
secondari
outcom
exclud
patient
infect
proven
elsewher
enrol
plausibl
respiratori
pathogen
poc
result
would
alter
lo
antibiot
use
patient
anoth
infect
diagnosi
made
analysi
conduct
r
multipl
imput
use
account
miss
data
use
packag
mice
studi
ran
januari
juli
plan
chang
made
studi
protocol
time
patient
met
elig
criteria
fig
sixtyon
patient
includ
intervent
arm
control
arm
discharg
enrol
interpret
unavail
three
declin
particip
one
patient
die
approach
one
patient
consent
test
perform
inform
miss
two
patient
patient
withdrew
studi
thu
patient
enrol
includ
analysi
control
arm
intervent
arm
statist
analys
prespecifi
posthoc
analys
baselin
characterist
similar
two
studi
arm
tabl
score
miss
patient
relev
omit
analysi
one
hundr
sixtyf
patient
neg
time
antibiot
chang
h
median
h
iqr
median
time
result
admiss
substanti
shorter
intervent
arm
compar
control
arm
control
arm
h
iqr
intervent
arm
h
iqr
twosampl
ttest
assum
unequ
varianc
p
ward
staff
grade
perform
poc
test
sampl
test
studi
investig
record
advers
event
report
overal
patient
posit
result
tabl
control
arm
intervent
arm
virus
bacteria
detect
shown
tabl
everi
viru
panel
identifi
except
parainfluenza
viru
type
type
type
singl
pathogen
detect
routin
test
detect
dual
infect
five
sampl
also
detect
coronavirus
detect
use
standard
test
three
four
invalid
test
control
intervent
arm
respect
remain
test
neg
control
intervent
pneumonia
bacterium
panel
identifi
four
patient
control
arm
elev
mycoplasma
cft
convalesc
serolog
sent
render
result
uninterpret
result
avail
ward
discharg
three
hospit
discharg
influenc
manag
tat
day
five
patient
intervent
arm
pneumonia
detect
antibiot
start
case
extend
discuss
microbiologist
evid
length
hospit
stay
primari
endpoint
reduc
poc
test
median
length
hospit
stay
h
iqr
control
arm
h
iqr
intervent
arm
linear
model
logtransform
length
stay
data
adjust
potenti
confound
rapid
test
associ
absolut
differ
natur
logarithm
length
stay
ci
p
correspond
ci
increas
length
stay
associ
rapid
test
arm
six
patient
test
mac
control
arm
patient
test
mac
intervent
arm
discharg
without
admiss
hospit
ward
one
secondari
outcom
evid
intervent
effect
tabl
prescrib
decis
within
h
follow
diagnost
result
investig
show
evid
differ
studi
arm
tabl
p
pearson
chisquar
test
pvalu
calcul
mont
carlo
replic
charlson
score
white
cell
count
l
fiftyon
patient
influenza
viru
andor
influenza
b
viru
detect
either
routin
assay
patient
control
arm
intervent
arm
given
antivir
time
first
dose
time
admiss
known
one
patient
arm
consider
reduc
intervent
arm
median
h
control
arm
iqr
h
intervent
arm
iqr
one
patient
arm
given
empir
antivir
virus
detect
plan
subgroup
analysi
exclud
patient
infect
proven
elsewher
enrol
eg
urinari
tract
infect
n
substanti
alter
result
found
evid
associ
respiratori
multiplex
pcr
biofir
poc
test
length
hospit
stay
compar
routin
laboratorybas
respiratori
pcr
serolog
test
associ
poc
test
antibiot
prescrib
decis
within
h
result
poc
test
also
produc
result
consider
faster
laboratorybas
assay
investig
whether
poc
result
actual
influenc
decis
make
associ
prescrib
decis
may
reflect
result
avail
antibiot
prescrib
prescrib
consid
result
decis
make
similar
percentag
patient
analys
neg
binomi
regress
model
adjust
age
sex
charlson
pott
score
day
week
admiss
valu
wcc
crp
use
multipl
imput
account
miss
data
score
avail
patient
therefor
adjust
statist
model
less
miss
data
covari
miss
outcom
variabl
antibiot
within
h
antibiot
time
miss
data
patient
control
arm
patient
intervent
arm
time
antibiot
first
h
miss
data
patient
intervent
arm
durat
antibiot
miss
data
patient
control
arm
intervent
arm
readmiss
miss
data
patient
intervent
arm
mortal
miss
data
patient
intervent
arm
control
arm
deescal
stop
antimicrobi
substitut
betalactam
narrow
spectrum
betalactam
intervent
arm
deescal
stop
antimicrobi
substitut
betalactam
narrow
spectrum
betalactam
substitut
betalactam
narrow
spectrum
betalactam
atyp
agent
stop
control
arm
escal
add
antibiot
exist
antibiot
agent
atyp
pneumonia
intervent
arm
escal
add
antibiot
exist
antibiot
agent
atyp
pneumonia
addit
agent
typic
pneumonia
atyp
agent
eg
betalactam
teicoplanin
ciprofloxacin
penicillin
allerg
substitut
betalactam
broader
spectrum
betalactam
receiv
antibiot
studi
arm
signific
differ
remain
secondari
outcom
two
studi
arm
hypothesi
poc
test
would
reduc
length
stay
howev
though
poc
test
day
faster
laboratorybas
test
result
avail
later
anticip
due
test
perform
took
min
relat
delay
process
specimen
clinic
staff
ward
sixtyeight
percent
poc
test
perform
studi
investig
reflect
fact
studi
protocol
initi
clinic
staff
soon
patient
admit
studi
ward
mani
case
instead
test
delay
studi
investig
visit
studi
ward
initi
studi
protocol
result
signific
delay
time
result
contrast
trial
mrsa
poc
screen
amu
ward
staff
tat
admiss
h
mrsa
test
mandatori
patient
elig
inclus
delay
present
studi
may
relat
screen
complex
elig
criteria
mrsa
studi
addit
relianc
studi
investig
present
ward
perform
test
case
tat
would
faster
embed
routin
diagnost
poc
test
ward
staff
perform
test
grade
perform
without
incid
other
report
tat
h
poc
test
though
tat
time
decis
test
time
result
test
conduct
trial
staff
thu
poc
test
success
implement
studi
fail
achiev
optimum
tat
poc
test
associ
reduct
time
antivir
identifi
influenza
viru
antivir
given
day
half
quicker
intervent
arm
within
day
admiss
given
drug
clinic
benefit
administ
within
h
symptom
onset
key
clinic
outcom
poc
test
allow
chang
therapi
appropri
treatment
mycoplasma
infect
control
arm
posit
result
uninterpret
predominantli
avail
discharg
abil
detect
coronavirus
allow
diagnosi
made
sampl
would
miss
use
routin
method
routin
test
identifi
singl
pathogen
oppos
identifi
dual
infect
patient
import
infect
control
viru
surveil
parainfluenza
viru
type
chlamydia
pneumonia
bordetella
pertussi
detect
cours
studi
span
entir
winter
posit
impact
antivir
faster
time
detect
influenza
report
observ
studi
paediatr
patient
given
oseltamivir
time
manner
possibl
compar
test
observ
studi
report
faster
time
neg
influenza
result
compar
anoth
rtpcr
h
versu
h
shorten
unnecessari
oseltamivir
use
day
estim
cost
save
per
patient
us
seventyf
percent
poc
result
neg
provid
inform
aetiolog
infect
predict
clinic
cours
neg
result
would
expect
expedit
discharg
antibiot
cessat
main
outcom
consider
paediatr
observ
studi
found
patient
posit
respiratori
viru
pcr
result
shorter
durat
intraven
antibiot
retrospect
studi
note
reduc
length
stay
children
posit
result
report
within
h
seen
neg
test
reduc
time
detect
influenza
laboratorybas
associ
significantli
lower
odd
ratio
admiss
length
stay
durat
antibiot
chest
xray
compar
posit
routin
test
retrospect
studi
adult
randomis
trial
note
patient
posit
poc
result
receiv
shorter
cours
antibiot
shorter
hospit
stay
neg
poc
result
posit
yield
may
studi
season
limit
extend
summer
month
record
type
rti
may
result
lower
expect
percentag
anoth
uk
adult
studi
septemb
februari
identifi
virus
patient
lower
rti
poc
result
slow
influenc
initi
antibiot
decis
make
median
time
antibiot
admiss
h
rapid
initi
antibiot
also
found
randomis
trial
poc
test
consist
guidelin
recommend
antibiot
treatment
cap
within
h
present
hospit
therefor
would
expect
almost
patient
initi
start
antibiot
howev
delay
poc
test
would
expect
paramet
impact
ie
test
done
appropri
time
frame
h
patient
evalu
subsequ
initi
discontinu
may
significantli
influenc
reflect
continu
studi
ward
antibiot
start
ed
even
posit
poc
result
amu
doctor
may
dissuad
safeti
ground
stop
deescal
antibiot
start
basi
clinic
assess
wit
ed
find
consist
randomis
trial
poc
test
found
mean
durat
antibiot
differ
control
arm
howev
group
identifi
greater
proport
patient
intervent
arm
poc
result
control
arm
receiv
singl
dose
antibiot
h
antibiot
someth
assess
present
studi
trial
rp
diagnost
adult
includ
found
pcr
detect
viral
pathogen
coupl
low
procalcitonin
level
led
antibiot
cessat
case
trend
toward
fewer
day
antibiot
treatment
offset
patient
antibiot
stop
author
latter
studi
advoc
realtim
stewardship
rp
result
omit
intervent
present
studi
rapid
pathogen
identif
antimicrobi
stewardship
associ
signific
reduct
hospit
cost
adult
inpati
studi
limit
nearli
due
limit
resourc
employ
pragmat
quasirandomis
design
alloc
patient
intervent
arm
even
day
make
studi
vulner
bia
due
differ
patient
alloc
studi
arm
though
found
evid
differ
outcom
analysi
adjust
sever
prespecifi
potenti
confound
fulli
randomis
design
would
provid
stronger
level
evid
patient
intervent
arm
suggest
patient
recruit
process
two
arm
equival
may
reflect
enthusiasm
may
also
reflect
increas
diseas
sever
intervent
arm
need
identifi
caus
diseas
therebi
result
bias
use
cohort
score
assess
therefor
accur
comparison
sever
pneumonia
two
arm
studi
could
determin
collect
data
type
rti
randomis
trial
poc
test
record
shorter
durat
antibiot
patient
asthma
copd
intervent
arm
versu
control
shorter
length
stay
copd
patient
arm
ed
routin
use
epma
know
exactli
mani
patient
receiv
antibiot
neg
time
antibiot
due
administr
error
chang
h
patient
howev
median
small
h
phenomenon
occur
studi
arm
similar
studi
subject
includ
routin
bacteriolog
result
analysi
howev
hypothesi
greater
depend
upon
predominantli
viral
panel
result
investig
bacteriolog
result
would
expect
differ
studi
arm
thu
influenc
result
final
number
elig
patient
admit
studi
ward
less
predict
data
use
plan
studi
henc
number
case
recruit
fell
short
statist
calcul
requir
patient
arm
detect
fall
day
clear
case
may
relat
patient
bypass
studi
ward
busi
winter
month
januari
march
due
inclus
summer
month
studi
select
patient
requir
admiss
possibl
antibiot
place
system
hospit
ward
panel
includ
common
bacteri
caus
lower
rti
would
probabl
identifi
pathogen
set
recent
studi
uk
identifi
bacteria
lower
respiratori
tract
specimen
patient
pneumonia
though
record
type
rti
studi
inpati
patient
probabl
lower
rti
studi
ed
might
test
greater
number
patient
viral
ill
poc
result
could
provid
reassur
discharg
reason
rapid
result
broader
rp
panel
afford
plausibl
safetynet
antibiot
prescript
would
reduc
due
mandat
maximum
wait
patient
english
ed
perceiv
lack
understand
result
vocalis
ed
staff
laboratorybas
test
patient
left
ed
result
avail
move
studi
one
step
hospit
highlight
import
knowledg
gap
edbas
studi
poc
test
incorpor
decis
make
support
therefor
advis
found
associ
respiratori
multiplex
pcr
biofir
poc
test
length
hospit
stay
compar
routin
laboratorybas
respiratori
pcr
serolog
test
result
like
influenc
delay
rapid
poc
test
poc
test
produc
result
consider
faster
routin
test
result
rapid
design
fault
poc
test
highlight
fact
new
technolog
enough
correct
system
must
place
order
reap
benefit
patient
poc
test
receiv
timecrit
antivir
influenza
significantli
faster
appropri
therapi
mycoplasma
infect
seen
control
arm
ward
staff
grade
perform
poc
test
without
incid
mean
test
potenti
across
rang
healthcar
studi
requir
focu
implement
respiratori
multiplex
pcr
poc
test
rapid
result
order
fulli
assess
impact
length
stay
antibiot
use
